Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer

Author(s):

In our exclusive interview, Sara M. Tolaney, MD, MPH, shares insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.

Welcome to a very special edition of OncLive^® On Air! I’m your host today, Jessica Hergert.

OncLive^® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of speaking with Sara M. Tolaney, MD, MPH, to discuss the use of neoadjuvant and adjuvant HER2-directed therapies, such as ado-trastuzumab emtansine (T-DM1; Kadcyla) and pertuzumab (Perjeta), in early-stage HER2-positive breast cancer.

In our exclusive interview, Dr. Tolaney, associate director of the Susan F. Smith Center for Women’s Cancers; director of Clinical Trials, Breast Oncology; and a senior physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, shared insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.